文献速递青光眼

评估将MYOC变异与常见变异联合用于基于遗传学的青光眼风险分层的实用方法

Evaluating Practical Approaches for Including MYOC Variants Alongside Common Variants for Genetics-Based Risk Stratification for Glaucoma.
PubMed 文献 · Am J Ophthalmol · 2025-03-08

该回顾性队列研究纳入58,452名参与者,评估基因分型芯片数据识别p.Gln368Ter携带者的方法,并分析将其整合入多基因风险评分(PRS)的价值。经质控后直接分型与测序结果完全一致,过滤后直接分型与填充结果仅16例不一致。将p.Gln368Ter纳入PRS可提高携带者被归为高风险的比例,但因变异罕见未改善一般人群的风险预测。

要点

  • 经质控过滤后,直接基因分型可准确识别p.Gln368Ter携带者,与测序结果完全一致。
  • 无法进行质控时,建议比较基因分型与填充结果以确保准确性。
  • 将p.Gln368Ter纳入PRS使QSKIN中携带者高风险比例从32.31%升至75.38%,CARTaGENE中从38.24%升至79.41%。

核心结论

  • 在实施严格质控措施的前提下,利用芯片数据可高精度地对p.Gln368Ter变异进行基因分型。
  • 将p.Gln368Ter纳入青光眼PRS改善了携带者的风险分层,但因该变异罕见未改善一般人群的风险预测。

研究设计与样本

  • 回顾性队列研究,纳入来自Genetics of Glaucoma、QSkin Sun and Health Study(QSKIN)和CARTaGENE项目的58,452名参与者,其中6,015名有测序数据。
  • 使用直接基因分型和填充数据识别p.Gln368Ter携带者,并在有测序数据的子集中确认结果。
  • 通过分层分析评估p.Gln368Ter状态与PRS的联合效应,分别将其作为两个独立因素和一个聚合评分。

主要发现

  • 缺乏适当质控时可能发生大量错误分型;但通过过滤调用率和杂合性,大多数情况下可准确分型p.Gln368Ter。
  • 在6,015名有测序数据的个体中,直接基因分型与测序结果完全一致。
  • 过滤后的直接基因分型与填充结果高度一致,57,468名个体中仅16例不一致。
  • 将p.Gln368Ter纳入PRS对高风险个体分层有额外效应,但因变异罕见未改善一般人群的风险预测。
  • MYOC增强PRS使QSKIN中p.Gln368Ter携带者被归为高风险的比例从32.31%升至75.38%,CARTaGENE中从38.24%升至79.41%。

关键数值与推荐

  • 当无法进行质控(如个体杂合性过滤)时,建议比较基因分型与填充结果以确保准确性。
  • 在6,015名有测序数据的个体中,直接基因分型与测序结果完全一致。
  • 过滤后直接基因分型与填充结果在57,468名个体中仅16例不一致。
  • MYOC增强PRS使QSKIN中携带者高风险比例从32.31%升至75.38%,CARTaGENE中从38.24%升至79.41%。

临床怎么用

  • 在实施严格质控(如过滤调用率和杂合性)的前提下,可利用芯片数据准确识别p.Gln368Ter携带者。
  • 当无法进行质控时,作者建议比较基因分型与填充结果以确保准确性。
  • 将p.Gln368Ter纳入PRS可改善携带者的风险分层,但因变异罕见未改善一般人群的风险预测。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Rare variants in the MYOC gene are associated with glaucoma risk, with p.Gln368Ter the most common pathogenic variant in Europeans. Genetics-based risk stratification may aid with early diagnosis for glaucoma but it is unclear how best to combine the p.Gln368Ter status with polygenic risk scores (PRS). Our study aimed to examine approaches for identifying p. Gln368Ter carriers using genotyping array data and the utility of integrating p.Gln368Ter status into glaucoma PRS. DESIGN: Retrospective cohort study. METHODS: We identified p.Gln368Ter carriers using directly genotyped and imputed data. Results were confirmed in a subset with sequencing data. We evaluated the combined effects of p.Gln368Ter status and PRS in stratified analyses by considering them as two separate factors and as an aggregate score. PARTICIPANTS: A total of 58,452 participants from the Genetics of Glaucoma, the QSkin Sun and Health Study (QSKIN), and CARTaGENE projects, including 6015 with sequencing data. MAIN OUTCOMES AND MEASURES: The concordance of direct genotyping, compared with imputation and sequencing for p.Gln368Ter identification. RESULTS: Without appropriate quality control, substantial mis-calling may occur. Nevertheless, the p.Gln368Ter variant could be accurately genotyped in most cases by filtering individuals for call rate and heterozygosity. In 6015 individuals with sequencing data, direct genotyping exhibited perfect concordance with sequencing results. Filtered direct genotyping results showed high agreement with imputed results, with only 16 discrepancies among 57,468 individuals. When quality control is not possible (eg, heterozygosity filtering for an individual), we recommend comparing genotyped and imputed results to ensure accuracy. Incorporating p.Gln368Ter into PRS had additional effects on stratifying high-risk individuals, but did not improve risk prediction for the general population given the variant's rarity. The MYOC-enhanced PRS increased the proportion of p.Gln368Ter carriers classified as high risk from 32.31% to 75.38% in QSKIN and from 38.24% to 79.41% in CARTaGENE. CONCLUSIONS: The p.Gln368Ter variant can be genotyped with high accuracy using array data, provided careful quality control measures are implemented. Incorporating p.Gln368Ter into glaucoma PRS improved risk stratification for carriers.

来源:Am J Ophthalmol,查看原文。版权归原作者所有。

引用

  1. Le NQ, He W, Law MH, et al. Evaluating Practical Approaches for Including MYOC Variants Alongside Common Variants for Genetics-Based Risk Stratification for Glaucoma. Am J Ophthalmol. 2025. PMID: 40064388. doi:10.1016/j.ajo.2025.03.011

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。